News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stealth Peptides Inc. Reports Successful Clinical Study of Oral Bendavia


1/22/2013 9:29:44 AM

BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for cardiovascular disease and its complications, announced today positive oral Bendavia™ clinical results. The Phase I clinical trial demonstrated that oral Bendavia achieved plasma concentrations shown to be cardioprotective in multiple models of acute and chronic cardiac diseases including heart failure. Bendavia is a compound that targets mitochondria to restore bioenergetics and organ function in cardiovascular and metabolic diseases.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES